Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy by Madhusudan Roy, Jing-Tang Lin, Sohidul Mondal, Mei-Chun Lin, Chih-Yu Leu, Yen-Lin Huang, Chen-Yuan Dong, Pei-Jen Lou

Subjects: Get full text

A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets by Lin Li, Xin Zhang, Jiayao Yan, Jingyi Guo, Fangcen Liu, Xiao Wei, Qin Liu, Kongcheng Wang, Baorui Liu

Subjects: Get full text

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Subjects: Get full text

PD-1/PD-L1及Treg细胞在JAK2V617F阳性骨髓增殖性肿瘤中的表达及意义 by 成志勇, 张丽军, 付建珠, 刘芳, 颜晓燕, 孙立娜, 孙雪珊, 王素云

Subjects: Get full text

PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages by Deyou Kong, Yongzhen Chen, Yajuan Yin, Zhikun Liu, Fang Yang, Xiaohong Li, Dongxing Shen, Jun Zhang

Subjects: “…PD-L1…”
Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

Subjects: Get full text

Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma by Shams ElDoha Galal ElDin Zaiema, Heba Mohamed Saber Hafez, Diaa El-Din Moussa Sherif Abou El-Ela, Rawda Ahmed Alaaeldin Ahmed Mohamed Saad

Subjects: Get full text

ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling by Aziguli Tulamaiti, Shu-Yu Xiao, Yan Yang, Musitaba Mutailifu, Xia-Qing Li, Shi-Qi Yin, Hong-Tai Ma, Hong-Fei Yao, Lin-Li Yao, Li-Peng Hu, Jun Li, Shu-Heng Jiang, Zhi-Gang Zhang, Yan-Miao Huo, Dong-Xue Li, Xue-Li Zhang

Subjects: Get full text

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective... by Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung

Subjects: Get full text

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Ca... by Kaewkedsri P, Intarawichian P, Jessadapattarakul S, Kunprom W, Koonmee S, Thanee M, Somintara O, Wongbuddha A, Chadbunchachai P, Nawapun S, Aphivatanasiri C

Subjects: Get full text

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival by Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Irene Krücken, Veit Zebralla, Veit Zebralla, Markus Pirlich, Markus Pirlich, Matthaeus Stoehr, Matthaeus Stoehr, Susanne Wiegand, Susanne Wiegand, Susanne Wiegand, Andreas Dietz, Andreas Dietz, Theresa Wald, Theresa Wald, Gunnar Wichmann, Gunnar Wichmann

Subjects: “…PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab…”
Get full text